FY2027 EPS Estimates for Amgen Decreased by Erste Group Bank

Amgen Inc. (NASDAQ:AMGN) – Analysts at Erste Group Bank lowered their FY2027 earnings per share (EPS) estimates for shares of Amgen in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will post earnings of $23.58 per share for the year, down from their prior forecast of $23.62. Erste Group Bank currently has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.31 per share.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.

Other equities analysts also recently issued reports about the company. Morgan Stanley reduced their price target on Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research report on Monday, July 6th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Finally, Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Trading Down 1.4%

Amgen stock opened at $366.29 on Friday. Amgen has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a market capitalization of $197.69 billion, a price-to-earnings ratio of 25.49, a price-to-earnings-growth ratio of 3.71 and a beta of 0.41. The business’s fifty day simple moving average is $347.69 and its two-hundred day simple moving average is $350.38. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Institutional Investors Weigh In On Amgen

Several large investors have recently bought and sold shares of AMGN. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC lifted its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Board of the Pension Protection Fund bought a new position in Amgen during the fourth quarter valued at approximately $26,000. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.